We have found that, in patients in whom there was a clinical deterioration following SARS-CoV-2 infection, the initial inflammatory response in the airway is blunted with reduced concentrations of IL-2, IL-33, IL-12, and IFN-α2a, in comparison with patients with COVID-19 without deterioration. This evidence concerns the gene IL33 and COVID-19.